Landfar Bio-medicine Co., Ltd

000504

CNE000000263

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
6.9 ^CNY	-4.83%		-11.76%	-40.52%

Apr. 11	Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million.	CI
2023	Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

NanHua Bio-medicine Co., Ltd's Equity Buyback announced on October 29, 2019, has expired.

October 27, 2020

The company expired its plan on October 28, 2020.

Latest news about Landfar Bio-medicine Co., Ltd

Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million.	Apr. 10	CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Landfar Bio Medicine’s Controlling Shareholder Boosts Stake to 30%	23-04-27	MT
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Landfar Bio-medicine Co., Ltd completed the acquisition of additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. for CNY 9.7 million.	22-12-09	CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-29	CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
NanHua Bio-medicine Co., Ltd announced that it expects to receive CNY 275.999987 million in funding from Hunan Chasing Fund Management Co., Ltd.	22-03-21	CI
NanHua Bio-medicine Co., Ltd signed a letter of intent to acquire Medicine-related assets from YanAn Bicon Pharmaceutical Listed Company.	21-12-09	CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-28	CI
NanHua Bio-medicine Co., Ltd's Equity Buyback announced on October 29, 2019, has expired.	20-10-27	CI
Hunan Finance Industry Fund Management Co., Ltd. cancelled the acquisition of 25.58% stake in NanHua Bio-medicine Co., Ltd. from Hunan Trust Co., Ltd.	20-10-09	CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-27	CI
Nanhua Bio-Medicine Co., Ltd Announces Election of Jian Wang as Non-Independent Director	20-05-19	CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-26	CI
Shanghai Shineton Investment Co., Ltd. completed the acquisition of 54% in Hunan ProMab Biotechnologies Co., Ltd. from NanHua Bio-medicine Co., Ltd..	19-12-16	CI
Hunan Xinghui Medical Investment Management Co., Ltd. cancelled the acquisition of 10.1% stake in NanHua Bio-medicine Co., Ltd. from Shanghai Heping Large Equity Investment Fund Management Limited.	19-12-09	CI
NanHua Bio-medicine Co., Ltd announces an Equity Buyback for CNY 100 million worth of its shares.	19-10-29	CI

Chart Landfar Bio-medicine Co., Ltd

Duration

Period

More charts

Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Companyâs biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Companyâs energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.

Sector

Healthcare Facilities & Services

Calendar

2024-04-24 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
LANDFAR BIO-MEDICINE CO., LTD	-40.52%	331M
SONIC HEALTHCARE LIMITED	-18.11%	8.02B
RADNET, INC.	+33.79%	3.51B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-29.02%	2.97B
SYNLAB AG	-7.71%	2.48B
DR. LAL PATHLABS LIMITED	-14.30%	2.23B
NEOGENOMICS, INC.	-16.38%	1.76B
FLEURY S.A.	-22.17%	1.44B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.69%	1.25B
ADICON HOLDINGS LIMITED	-11.20%	1.11B

Medical & Diagnostic Laboratories

Landfar Bio-medicine Co., Ltd

Equities

000504

CNE000000263

Healthcare Facilities & Services

NanHua Bio-medicine Co., Ltd's Equity Buyback announced on October 29, 2019, has expired.

Latest news about Landfar Bio-medicine Co., Ltd

Chart Landfar Bio-medicine Co., Ltd

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Medical & Diagnostic Laboratories